1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pak Fah Yeow International Limited

Pak Fah Yeow International Limited

HHKEX:239
2.38
HKD
-0.02
(-0.83%)
738.59MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.52
0.6
0.58
0.59
0.57
0.45
0.48
0.35
0.45
0.47
0.83
0.76
0.69
- -
Basic EPS, GAAP
0.23
0.47
0.2
0.2
0.33
0.12
0.12
-0.12
0.12
0.1
0.34
0.25
0.29
- -
Free Cash Flow per Basic Share
0.17
0.13
0.23
0.21
0.31
0.17
0.16
0.02
0.22
0.13
0.46
0.25
0.36
- -
Dividend per Share
0.14
0.16
0.18
0.12
0.13
0.14
0.11
0.08
0.07
0.08
0.15
0.21
0.19
- -
Book Value per Share
1.66
2
2
2.03
2.4
2.43
2.44
2.16
2.27
2.27
2.46
2.35
2.32
2.32
Tangible Book Value per Share
1.65
1.99
2
2.02
2.39
2.42
2.43
2.15
2.26
2.26
2.45
2.34
2.31
2.31
Basic Weighted Avg Shares
312
312
312
312
312
312
312
312
312
312
312
312
312
312
Sales/Revenue/Turnover
161
186
182
183
179
142
148
110
140
147
259
237
214
- -
Operating Margin (%)
35.36
38.87
43.38
42.52
40.72
24.91
30.38
28.19
32.64
33.04
55.22
52.97
51.25
- -
Depreciation Expense
2
2
2
2
2
8
8
8
7
7
7
7
6
- -
Net Income, GAAP
71
146
61
61
103
37
36
-38
38
30
105
79
91
- -
Effective Tax Rate (%)
11.11
7.5
17.18
17.19
9.14
14.74
18.56
- -
18.62
20.69
18.45
19.57
15.05
- -
Profit Margin (%)
44.03
78.6
33.55
33.51
57.35
26.33
24.34
-35.03
27.24
20.33
40.51
33.19
42.68
- -
Working Capital
13
47
69
95
126
118
132
147
175
194
273
318
367
367
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
517
623
624
634
749
757
760
673
708
707
765
732
723
723
Return on Invested Capital (%)
8.87
14.26
9.27
9.36
14.38
4.89
4.7
- -
5.44
4.23
14.07
13.02
13
- -
Return on Capital (%)
13.04
23.92
9.32
9.37
14.39
4.89
4.71
- -
5.46
4.24
14.24
10.5
12.55
- -
Return on Common Equity (%)
14.26
25.71
9.79
9.73
14.85
4.95
4.75
-5.35
5.53
4.23
14.27
10.5
12.56
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
4
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
312
312
312
Market Capitalization
773
785
739

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
339
397
388
Cash, Cash Equivalents & STI
290
362
345
Accounts Receivable, Net
19
10
12
Inventories
12
16
13
Total Current Liabilities
21
61
21
Payables & Accruals
- -
- -
- -
ST Debt
4
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.74%
1.53%
-1.25%
Free Cash Flow
93.21%
206.3%
43.98%
Net Income, GAAP
-18.49%
4.11%
16.17%
Sales/Revenue/Turnover
4.68%
18.16%
-9.67%
Total Cash Common Dividend
5.58%
23.51%
-13.71%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
259
2024
- -
- -
237
2025
- -
- -
214

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.34
2024
- -
- -
0.25
2025
- -
- -
0.29

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.15
2024
- -
- -
0.21
2025
- -
- -
0.19

Company Description

Company Profile APIChatGPT
CEO
Wee Sean Gan
Full Time Employees
100
Sector
Health technology
Industry
Pharmaceuticals: major
Address
200 Gloucester Road Hong Kong Hong Kong
IPO Date
Dec 18, 1991
Website
pakfahyeow.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pak Fah Yeow International Limited (0239.HK) is an investment holding company principally engaged in the manufacture, marketing, and distribution of healthcare products under the Hoe Hin brand; property investments; and treasury investments including equity and debt securities, mutual funds, and dual currency investments. The company offers a diverse portfolio of medicated oils, balms, and ointments such as Hoe Hin White Flower Embrocation (also known as Hoe Hin Pak Fah Yeow), Hoe Hin Strain Relief, Hoe Hin White Flower Ointment, and Fúzai 239 (floral-scented White Flower Embrocation); these products provide relief from headaches, muscular pain, colds, insect bites, and strains, with manufacturing certified under PIC/S GMP, ISO 9001:2015, Therapeutic Goods Administration Australia, and Chinese Medicine Council of Hong Kong standards. It operates healthcare sales in Hong Kong, Macau, the People's Republic of China (including e-commerce expansion), Southeast Asia (notably Philippines and Singapore growth), North America (USA facing potential 2025 tariff risks), the United Kingdom, and internationally; property investments encompass commercial office, industrial, residential, and car park assets in Hong Kong, Singapore, and the United Kingdom; treasury activities focus on fixed deposits and surplus cash optimization. Founded in 1927 and headquartered at 11th Floor, 200 Gloucester Road, Wan Chai, Hong Kong (registered office in Bermuda), the company reported 2024 revenue of HK$236.8 million (down 8.6% year-on-year, with healthcare at 91.8%), underlying recurring profit of HK$103.6 million (down 13.0%), and proposed total dividends of HK20.0 cents per share amid softer China demand post-pandemic, Hong Kong rental pressures, and treasury gains from higher interest; it enhanced digital marketing, online channels in China, and production capacity supporting North America growth while maintaining full occupancy in UK/Singapore properties. No major acquisitions, partnerships, funding rounds, or new product launches occurred in 2024-2025; strategic focus remains on healthcare market expansion, e-commerce acceleration, and prudent asset management.